- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Varian Medical acquires software developer
Argus Software, a supplier of specialized radiotherapy and diagnostic imaging software, has become part of the oncology systems business of Varian Medical Systems. The privately held company's software automates the collection of quality control and test
Argus Software, a supplier of specialized radiotherapy and diagnostic imaging software, has become part of the oncology systems business of Varian Medical Systems. The privately held company's software automates the collection of quality control and test data for radiation equipment. Details of the acquisition, which was announced Jan. 16, were not disclosed. Argus software will be added to Varian's radiation oncology products, according to the company. The acquisition could reduce Varian's time-to-market for future products, including a software module capable of automating intensity-modulated radiation therapy (IMRT), the company said. This module could accelerate the clinical adoption of IMRT, which is already moving fast. The number of cancer centers offering Varian's IMRT product SmartBeam more than doubled to 92 in 2001 from 40 the year before.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
